Literature DB >> 33415417

Efficacy of a Glass Membrane Emulsification Device to Form Mixture of Cisplatin Powder with Lipiodol on Transarterial Therapy for Hepatocellular Carcinoma.

Toshihiro Tanaka1, Hideki Iwamoto2,3, Mitsuteru Fujihara4, Hideyuki Nishiofuku5, Tetsuya Masada5, Hiroyuki Suzuki2, Hironori Koga2, Takuji Torimura2, Kimihiko Kichikawa5.   

Abstract

PURPOSE: To examine physiochemical characteristics and drug release properties of cisplatin powder and lipiodol mixtures formed by a glass membrane emulsification device compared with a 3-way stopcock.
MATERIALS AND METHODS: Seven different types of mixtures were evaluated: cisplatin powder and lipiodol directly mixed (suspension), complete cisplatin solution and lipiodol mixed by a 3-way stopcock or the device (emulsion), incomplete cisplatin solution and lipiodol mixed by a 3-way stopcock or the device (solid-in-water emulsion), and contrast material and cisplatin suspension mixed by a 3-way stopcock or the device (solid-in-oil emulsion). RESULT: The percentages of water-in-oil were 98.08 ± 0.27% in the emulsion formed by the device, while 70.3 ± 4.63% in the emulsion formed by a 3-way stopcock (P = 0.037). Solid-in-water and solid-in-oil emulsions formed by the device showed 98.09 ± 0.38% and 98.70 ± 0.40% of water-in-oil, respectively, whereas both solid-in-water and solid-in-oil emulsions formed by a 3-way stopcock showed 0.00%. Homogenous droplet sizes were shown by using the device. The half release times of cisplatin in the emulsions formed by the device were 197 ± 19, 244 ± 24 and 478 ± 52 min, respectively, which were significantly longer than the emulsion formed by a 3-way stopcock of 8 ± 8 min (P = 0.046-0.050). Suspension showed the longest release time; however, the viscosity was lowest.
CONCLUSION: The glass membrane emulsification device formed almost 100% water-in-oil, whereas 3-way stopcock produced 100% oil-in-water when incomplete solution or suspension was mixed. Slower cisplatin release was shown in the emulsions formed by the device.

Entities:  

Keywords:  Arterial embolization; Cisplatin; Emulsion; Hepatocellular carcinoma; Lipiodol

Mesh:

Substances:

Year:  2021        PMID: 33415417     DOI: 10.1007/s00270-020-02757-2

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  5 in total

1.  Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature.

Authors:  Yasunobu Takaki; Toshio Kaminou; Masanobu Shabana; Takashi Ihaya; Kenji Otsubo; Toshihide Ogawa
Journal:  Hepatogastroenterology       Date:  2008 Jan-Feb

2.  Size of lipid microdroplets effects results of hepatic arterial chemotherapy with an anticancer agent in water-in-oil-in-water emulsion to hepatocellular carcinoma.

Authors:  S Higashi; N Tabata; K H Kondo; Y Maeda; M Shimizu; T Nakashima; T Setoguchi
Journal:  J Pharmacol Exp Ther       Date:  1999-05       Impact factor: 4.030

3.  Transcatheter arterial chemoembolization with fine-powder cisplatin-lipiodol for HCC.

Authors:  Yohei Koizumi; Masashi Hirooka; Takahide Uehara; Yoshiyasu Kisaka; Kazuhiro Uesugi; Teru Kumagi; Masanori Abe; Bunzo Matsuura; Yoichi Hiasa; Morikazu Onji
Journal:  Hepatogastroenterology       Date:  2011 Mar-Apr

4.  Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study.

Authors:  Masahito Nakano; Takashi Niizeki; Hiroaki Nagamatsu; Masatoshi Tanaka; Ryoko Kuromatsu; Manabu Satani; Shusuke Okamura; Hideki Iwamoto; Shigeo Shimose; Tomotake Shirono; Yu Noda; Hironori Koga; Takuji Torimura
Journal:  Mol Clin Oncol       Date:  2017-10-04

5.  Clinical utility of transarterial infusion chemotherapy using cisplatin-lipiodol emulsion for unresectable hepatocellular carcinoma.

Authors:  Tetsuya Beppu; Kazushi Sugimoto; Katsuya Shiraki; Masahiko Tameda; Yuji Inagaki; Suguru Ogura; Chika Kasai; Satoko Kusagawa; Keiichiro Nojiri; Misao Yoneda; Hiroyuki Fuke; Norihiko Yamamoto; Yoshiyuki Takei; Masashi Fujimori; Takaaki Hasegawa; Takashi Yamanaka; Junichi Uraki; Masataka Kashima; Haruyuki Takaki; Atsuhiro Nakatsuka; Koichiro Yamakado; Kan Takeda
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.